A phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B-cell malignancies Meeting Abstract
| Authors: | Samaniego, F.; Burke, J. M.; Mahadevan, D.; Cherry, M.; Sadiq, A. A.; Koontz, M. Z.; Villasboas, J. C.; Reid, E.; Cull, E.; Priego, V.; Roeker, L. E.; Cobb, P.; Melear, J.; Conkling, P.; Cosgrove, D.; Zhang, H. Y.; Rastgoo, N.; Benbatoul, K.; Haney, D. N.; Jin, Y. Y.; Marango, J.; Howell, S. B.; Rice, W. G.; Bejar, R. |
| Abstract Title: | A phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B-cell malignancies |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398805083 |
| DOI: | 10.1182/blood-2021-148827 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1355 -- Hybrid meeting, also took place online -- Source: Wos |
